199 related articles for article (PubMed ID: 17363734)
1. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.
Proost P; Mortier A; Loos T; Vandercappellen J; Gouwy M; Ronsse I; Schutyser E; Put W; Parmentier M; Struyf S; Van Damme J
Blood; 2007 Jul; 110(1):37-44. PubMed ID: 17363734
[TBL] [Abstract][Full Text] [Related]
2. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.
Proost P; Schutyser E; Menten P; Struyf S; Wuyts A; Opdenakker G; Detheux M; Parmentier M; Durinx C; Lambeir AM; Neyts J; Liekens S; Maudgal PC; Billiau A; Van Damme J
Blood; 2001 Dec; 98(13):3554-61. PubMed ID: 11739156
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.
Ludwig A; Schiemann F; Mentlein R; Lindner B; Brandt E
J Leukoc Biol; 2002 Jul; 72(1):183-91. PubMed ID: 12101279
[TBL] [Abstract][Full Text] [Related]
4. Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity.
Hensbergen PJ; van der Raaij-Helmer EM; Dijkman R; van der Schors RC; Werner-Felmayer G; Boorsma DM; Scheper RJ; Willemze R; Tensen CP
Eur J Biochem; 2001 Sep; 268(18):4992-9. PubMed ID: 11559369
[TBL] [Abstract][Full Text] [Related]
5. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis.
Loos T; Dekeyzer L; Struyf S; Schutyser E; Gijsbers K; Gouwy M; Fraeyman A; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J; Proost P
Lab Invest; 2006 Sep; 86(9):902-16. PubMed ID: 16847431
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
[TBL] [Abstract][Full Text] [Related]
7. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
[TBL] [Abstract][Full Text] [Related]
8. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).
Sauty A; Colvin RA; Wagner L; Rochat S; Spertini F; Luster AD
J Immunol; 2001 Dec; 167(12):7084-93. PubMed ID: 11739530
[TBL] [Abstract][Full Text] [Related]
9. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.
Proost P; Struyf S; Loos T; Gouwy M; Schutyser E; Conings R; Ronsse I; Parmentier M; Grillet B; Opdenakker G; Balzarini J; Van Damme J
Arthritis Res Ther; 2006; 8(4):R107. PubMed ID: 16846531
[TBL] [Abstract][Full Text] [Related]
10. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
[TBL] [Abstract][Full Text] [Related]
11. Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands.
McColl SR; Mahalingam S; Staykova M; Tylaska LA; Fisher KE; Strick CA; Gladue RP; Neote KS; Willenborg DO
Lab Invest; 2004 Nov; 84(11):1418-29. PubMed ID: 15322564
[TBL] [Abstract][Full Text] [Related]
12. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
[TBL] [Abstract][Full Text] [Related]
13. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
Costantini S; Raucci R; De Vero T; Castello G; Colonna G
Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
[TBL] [Abstract][Full Text] [Related]
14. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7.
Puchert M; Obst J; Koch C; Zieger K; Engele J
Cytokine; 2020 Jan; 125():154809. PubMed ID: 31437604
[TBL] [Abstract][Full Text] [Related]
15. Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling.
Metzemaekers M; Mortier A; Janssens R; Boff D; Vanbrabant L; Lamoen N; Van Damme J; Teixeira MM; De Meester I; Amaral FA; Proost P
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703769
[TBL] [Abstract][Full Text] [Related]
16. The expression and possible roles of chemokine CXCL11 and its receptor CXCR3 in the human endometrium.
Hirota Y; Osuga Y; Koga K; Yoshino O; Hirata T; Morimoto C; Harada M; Takemura Y; Nose E; Yano T; Tsutsumi O; Taketani Y
J Immunol; 2006 Dec; 177(12):8813-21. PubMed ID: 17142784
[TBL] [Abstract][Full Text] [Related]
17. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands.
Clark-Lewis I; Mattioli I; Gong JH; Loetscher P
J Biol Chem; 2003 Jan; 278(1):289-95. PubMed ID: 12417585
[TBL] [Abstract][Full Text] [Related]
18. Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture.
Berencsi K; Meropol NJ; Hoffman JP; Sigurdson E; Giles L; Rani P; Somasundaram R; Zhang T; Kalabis J; Caputo L; Furth E; Swoboda R; Marincola F; Herlyn D
Cancer Immunol Immunother; 2007 Mar; 56(3):359-70. PubMed ID: 16783574
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H
Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685
[TBL] [Abstract][Full Text] [Related]
20. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states.
Cox MA; Jenh CH; Gonsiorek W; Fine J; Narula SK; Zavodny PJ; Hipkin RW
Mol Pharmacol; 2001 Apr; 59(4):707-15. PubMed ID: 11259614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
